SpringWorks rises after FDA approves drug treating non-cancerous tumors in adults

SpringWorks Therapeutics

27/11/2023 23:12

** Shares of drug developer SpringWorks Therapeutics
 SWTX.O  rise 25.18% to $26 after market
    ** U.S. Food and Drug Administration approves SpringWorks
Therapeutics' drug for treating a type of non-cancerous
soft-tissue tumor in adults 
    ** The company expects the monotherapy nirogacestat, branded
as Ogsiveo, to be available in the United States within 10 days
of approval
    ** Seven of 7 brokerages rate the stock "buy" or higher;
their median PT is $47
    ** YTD, SpringWorks down 20.26%

 (Reporting by Abhinav Parmar)
 ((Abhinav.parmar@thomsonreuters.com))